Quest for the right Drug

|
עמוד הבית / הומלוג מיקס 50 קוויק פן / מידע מעלון לרופא

הומלוג מיקס 50 קוויק פן HUMALOG MIX 50 KWIKPEN (INSULIN LISPRO, INSULIN LISPRO AS PROTAMINE)

תרופה במרשם תרופה בסל נרקוטיקה ציטוטוקסיקה

צורת מתן:

תת-עורי : S.C

צורת מינון:

תרחיף להזרקה : SUSPENSION FOR INJECTION

Special Warning : אזהרת שימוש

4.4     Special warnings and precautions for use

Traceability
In order to improve the traceability of biological medicinal products, the name and the batch number of the administered product should be clearly recorded.

Under no circumstances should Humalog Mix 25 or Humalog Mix 50 be given intravenously.

Transferring a patient to another type or brand of insulin
Transferring a patient to another type or brand of insulin should be done under strict medical supervision.
Changes in strength, brand (manufacturer), type (regular/soluble, NPH/isophane, etc.), species (animal, human, human insulin analogue), and/or method of manufacture (recombinant DNA versus animal-source insulin) may result in the need for a change in dosage.

Hypoglycaemia and hyperglycaemia
Conditions which may make the early warning symptoms of hypoglycaemia different or less pronounced include long duration of diabetes, intensified insulin therapy, diabetic nerve disease or medications such as beta-blockers.

A few patients who have experienced hypoglycaemic reactions after transfer from animal-source insulin to human insulin have reported that the early warning symptoms of hypoglycaemia were less pronounced or different from those experienced with their previous insulin. Uncorrected hypoglycaemic or hyperglycaemic reactions can cause loss of consciousness, coma, or death.

The use of dosages which are inadequate or discontinuation of treatment, especially in insulin-dependent diabetics, may lead to hyperglycaemia and diabetic ketoacidosis; conditions which are potentially lethal.

Injection technique
Patients must be instructed to perform continuous rotation of the injection site to reduce the risk of developing lipodystrophy and cutaneous amyloidosis. There is a potential risk of delayed insulin absorption and worsened glycaemic control following insulin injections at sites with these reactions. A sudden change in the injection site to an unaffected area has been reported to result in hypoglycaemia.
Blood glucose monitoring is recommended after the change in the injection site, and dose adjustment of antidiabetic medications may be considered.

Insulin requirements and dosage adjustment
Insulin requirements may be increased during illness or emotional disturbances.

Adjustment of dosage may also be necessary if patients undertake increased physical activity or change their usual diet. Exercise taken immediately after a meal may increase the risk of hypoglycaemia.

Combination of Humalog Mix 25 or Humalog Mix 50 with pioglitazone:
Cases of cardiac failure have been reported when pioglitazone was used in combination with insulin, especially in patients with risk factors for development of cardiac heart failure. This should be kept in mind, if treatment with the combination of pioglitazone and Humalog Mix is considered. If the combination is used, patients should be observed for signs and symptoms of heart failure, weight gain and oedema. Pioglitazone should be discontinued, if any deterioration in cardiac symptoms occurs.

Avoidance of medication errors
Patients must be instructed to always check the insulin label before each injection to avoid accidental mix-ups between the two different strengths of Humalog KwikPen as well as other insulin products.

Patients must visually verify the dialled units on the dose counter of the pen. Therefore, the requirement for patients to self-inject is that they can read the dose counter on the pen. Patients who are blind or have poor vision must be instructed to always get help/assistance from another person who has good vision and is trained in using the insulin device.
Excipients
This medicinal product contains less than 1 mmol sodium (23 mg) per dose, i.e., essentially “sodium-free”.

Effects on Driving

4.7     Effects on ability to drive and use machines

The patient’s ability to concentrate and react may be impaired as a result of hypoglycaemia. This may constitute a risk in situations where these abilities are of special importance (e.g. driving a car or operating machinery).


Patients should be advised to take precautions to avoid hypoglycaemia whilst driving, this is particularly important in those who have reduced or absent awareness of the warning signs of hypoglycaemia or have frequent episodes of hypoglycaemia. The advisability of driving should be considered in these circumstances.

מסגרת הכללה בסל

התוויות הכלולות במסגרת הסל

התוויה תאריך הכללה תחום קליני Class Effect מצב מחלה
התרופה האמורה תינתן לטיפול בחולי סוכרת. 09/03/1999 מחלות מטבוליות INSULIN ASPART, INSULIN LISPRO, INSULIN GLULISINE
שימוש לפי פנקס קופ''ח כללית 1994 לא צוין
תאריך הכללה מקורי בסל לא צוין
הגבלות לא צוין

בעל רישום

ELI LILLY ISRAEL LTD, ISRAEL

רישום

143 46 33218 00

מחיר

0 ₪

מידע נוסף

עלון מידע לרופא

13.07.21 - עלון לרופא

עלון מידע לצרכן

03.06.20 - עלון לצרכן אנגלית 11.08.22 - עלון לצרכן אנגלית 03.06.20 - עלון לצרכן עברית 11.08.22 - עלון לצרכן עברית 03.06.20 - עלון לצרכן ערבית 11.08.22 - עלון לצרכן ערבית 19.01.22 - עלון לצרכן אנגלית 19.01.22 - עלון לצרכן עברית 19.01.22 - עלון לצרכן ערבית 03.06.20 - החמרה לעלון 03.06.20 - החמרה לעלון 03.06.20 - החמרה לעלון 03.06.20 - החמרה לעלון 10.11.20 - החמרה לעלון 08.06.15 - החמרה לעלון

לתרופה במאגר משרד הבריאות

הומלוג מיקס 50 קוויק פן

קישורים נוספים

RxList WebMD Drugs.com